Home › Depression › NCT05699226
Amplitude Titration to Improve ECT Clinical Outcomes
Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial
Who can join
Ages 50 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of major depressive disorder or bipolar II * Clinical indications for ECT with right unilateral electrode placement Exclusion Criteria: * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease) * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder) * Current drug or alcohol use disorder (except for nicotine) * Contraindications to MRI.
About the study
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT:
H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2).
H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency
What is being tested
- Soterix Medical Incorporated 4x1 adapter (device)
- Traditional ECT device (device)
Sponsor: University of New Mexico · Participants: 50 · Started: Sep 14, 2023
Contact the study team
- Chris Abbott, MD · Phone: 5052720406
- Megan Lloyd, MS · Phone: (505) 272-3507
Official record on ClinicalTrials.gov — NCT05699226
Locations in the U.S.
| New Mexico | University of New Mexico Health Science Center, Albuquerque |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.